Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Wealthfront Advisers LLC

Wealthfront Advisers LLC reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 47.9% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 6,371 shares of the life sciences company's stock after selling 5,852 shares during the period. Wealthfront Advisers LLC's holdings in Illumina were worth $505,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. Diversified Trust Co purchased a new position in Illumina in the first quarter valued at approximately $355,000. State of Alaska Department of Revenue increased its stake in Illumina by 2.5% in the first quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company's stock valued at $1,469,000 after acquiring an additional 445 shares during the last quarter. Merit Financial Group LLC increased its stake in Illumina by 344.8% in the first quarter. Merit Financial Group LLC now owns 13,036 shares of the life sciences company's stock valued at $1,034,000 after acquiring an additional 10,105 shares during the last quarter. Trexquant Investment LP grew its stake in shares of Illumina by 16.7% during the fourth quarter. Trexquant Investment LP now owns 142,977 shares of the life sciences company's stock valued at $19,106,000 after buying an additional 20,506 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its stake in shares of Illumina by 15.1% during the first quarter. Robeco Institutional Asset Management B.V. now owns 516,293 shares of the life sciences company's stock valued at $40,963,000 after buying an additional 67,676 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Analyst Ratings Changes

ILMN has been the topic of several recent analyst reports. Stephens reissued an "overweight" rating and issued a $105.00 target price on shares of Illumina in a research note on Tuesday, May 20th. JPMorgan Chase & Co. lowered their target price on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Scotiabank lowered shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 target price for the company. in a report on Friday, July 11th. Morgan Stanley reduced their price target on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a research report on Monday, May 12th. Finally, Canaccord Genuity Group raised their price target on shares of Illumina from $87.00 to $99.00 and gave the company a "hold" rating in a research report on Wednesday, June 11th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $125.11.

Insider Buying and Selling at Illumina

In other news, CFO Ankur Dhingra acquired 6,100 shares of the firm's stock in a transaction on Monday, May 12th. The stock was acquired at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the transaction, the chief financial officer owned 24,906 shares in the company, valued at approximately $2,022,616.26. The trade was a 32.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.60% of the company's stock.

Illumina Trading Up 2.2%

Illumina stock traded up $2.25 during midday trading on Thursday, reaching $106.86. The stock had a trading volume of 568,298 shares, compared to its average volume of 2,394,282. The company has a quick ratio of 1.48, a current ratio of 1.86 and a debt-to-equity ratio of 0.63. The firm has a market cap of $16.92 billion, a price-to-earnings ratio of -17.62, a price-to-earnings-growth ratio of 1.99 and a beta of 1.36. The company has a fifty day moving average of $90.45 and a 200 day moving average of $94.51. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The business's quarterly revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.98 earnings per share. On average, analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.